The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Open accessAbstract
Advances in early detection, prevention, and treatment have resulted in consistently falling cancer death rates in the United States. In parallel with these advances have come significant increases in the cost of cancer care. It is well established that the cost of health care (including cancer care) in the United States is growing more rapidly than the overall economy. In part, this is a result of the prices and rapid uptake of new agents and other technologies, including advances in imaging and therapeutic radiology. Conventional understanding suggests that high prices may reflect the costs and risks associated with the development, production, and marketing of new drugs and technologies, many of which are valued highly by physicians, patients, and payers. The increasing cost of cancer care impacts many stakeholders who play a role in a complex health care system. Our patients are the most vulnerable because they often experience uneven insurance coverage, leading to financial strain or even ruin. Other key groups include pharmaceutical manufacturers that pass along research, development, and marketing costs to the consumer; providers of cancer care who dispense increasingly expensive drugs and technologies; and the insurance industry, which ultimately passes costs to consumers. Increasingly, the economic burden of health care in general, and high-quality cancer care in particular, will be less and less affordable for an increasing number of Americans unless steps are taken to curb current trends. The American Society of Clinical Oncology (ASCO) is committed to improving cancer prevention, diagnosis, and treatment and eliminating disparities in cancer care through support of evidence-based and cost-effective practices. To address this goal, ASCO established a Cost of Care Task Force, which has developed this Guidance Statement on the Cost of Cancer Care. This Guidance Statement provides a concise overview of the economic issues facing stakeholders in the cancer community. It also recommends that the following steps be taken to address immediate needs: recognition that patient-physician discussions regarding the cost of care are an important component of high-quality care; the design of educational and support tools for oncology providers to promote effective communication about costs with patients; and the development of resources to help educate patients about the high cost of cancer care to help guide their decision making regarding treatment options. Looking to the future, this Guidance Statement also recommends that ASCO develop policy positions to address the underlying factors contributing to the increased cost of cancer care. Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Medical Care Costs: How Much Welfare Loss?
Newhouse, J. P. (1992) · Journal of Economic Perspectives · doi:10.1257/jep.6.3.3 · Cited by 1,211
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Association of Insurance with Cancer Care Utilization and Outcomes
Ward, E., Halpern, M., Schrag, N., Cokkinides, V., DeSantis, C., Bandi, P., Siegel, R., Stewart, A., & Jemal, A. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0011 · Cited by 724
Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs
(2008) · National Academies Press eBooks · doi:10.17226/11993 · Cited by 708
Cost of Care for Elderly Cancer Patients in the United States
Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L., Topor, M., Meekins, A., & Brown, M. L. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn103 · Cited by 700
Himmelstein, D. U., Warren, E., Thorne, D., & Woolhandler, S. (2005) · Health Affairs · doi:10.1377/hlthaff.w5.63 · Cited by 529
Toward The ‘Tipping Point’: Decision Aids And Informed Patient Choice
O’Connor, A. M., Wennberg, J. E., Legare, F., Llewellyn-Thomas, H. A., Moulton, B. W., Sepucha, K. R., Sodano, A. G., & King, J. S. (2007) · Health Affairs · doi:10.1377/hlthaff.26.3.716 · Cited by 445
Hillner, B. E., Siegel, B. A., Liu, D., Shields, A. F., Gareen, I. F., Hanna, L., Stine, S. H., & Coleman, R. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5631 · Cited by 374
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Self-citationMedicare and Cost-Effectiveness Analysis
Neumann, P. J., Rosen, A. B., & Weinstein, M. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsb050564 · Cited by 225
Banthin, J. S., & Bernard, D. M. (2006) · JAMA · doi:10.1001/jama.296.22.2712 · Cited by 201
Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey
Schrag, D., & Hanger, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2437 · Cited by 194
Self-citationKeehan, S., Sisko, A., Truffer, C., Smith, S., Cowan, C., Poisal, J., Clemens, M. K., & the National Health Expenditure Accounts Projections Team (2008) · Health Affairs · doi:10.1377/hlthaff.27.2.w145 · Cited by 194
Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans
Doshi, J. A., Zhu, J., Lee, B. Y., Kimmel, S. E., & Volpp, K. G. (2009) · Circulation · doi:10.1161/circulationaha.108.783944 · Cited by 184
Barriers to patient-physician communication about out-of-pocket costs
Alexander, G. C., Casalino, L. P., Tseng, C.-W., McFadden, D., & Meltzer, D. O. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30249.x · Cited by 174
Schneeweiß, S., Patrick, A. R., Maclure, M., Dormuth, C. R., & Glynn, R. J. (2007) · Circulation · doi:10.1161/circulationaha.106.665992 · Cited by 145
Developing A Center For Comparative Effectiveness Information
Wilensky, G. R. (2006) · Health Affairs · doi:10.1377/hlthaff.25.w572 · Cited by 134
Increasing Health Insurance Costs and the Decline in Insurance Coverage
Chernew, M. E., Cutler, D., & Keenan, P. S. (2005) · Health Services Research · doi:10.1111/j.1475-6773.2005.00409.x · Cited by 134
Hartman, M., Martin, A., McDonnell, P., & Catlin, A. (2009) · Health Affairs · doi:10.1377/hlthaff.28.1.246 · Cited by 123
The effects of prescription drug copayments on statin adherence.
Gibson, T. B., Mark, T. L., McGuigan, K. A., Axelsen, K. J., & Wang, S. S. (2006) · PubMed · Cited by 101
Cost implications of new treatments for advanced colorectal cancer
Wong, Y., Meropol, N. J., Speier, W. F., Sargent, D. J., Goldberg, R. M., & Beck, J. R. (2009) · Cancer · doi:10.1002/cncr.24246 · Cited by 62
Self-citationInterpreting the Economic Literature in Oncology
Grusenmeyer, P. A., & Wong, Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0738 · Cited by 45
SPIKE$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care
McFarlane, J. J., Riggins, J., & Smith, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6208 · Cited by 44
Self-citationProjecting future drug expenditures—2009
Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Martin, P. K., Blake, S., Matusiak, L. M., Hunkler, R. J., & Schumock, G. T. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080636 · Cited by 43
Projecting future drug expenditures—2008
Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Doloresco, F., Grim, P., Hunkler, R. J., Hontz, K. M., & Schumock, G. T. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070629 · Cited by 43
Value of High-Cost Cancer Care: A Behavioral Science Perspective
Weinfurt, K. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9029 · Cited by 33
Rethinking Professional Ethics in the Cost-Sharing Era
Alexander, G. C., Hall, M. A., & Lantos, J. D. (2006) · The American Journal of Bioethics · doi:10.1080/15265160600755813 · Cited by 26
An Exploration of Relative Health Stock in Advanced Cancer Patients
Gaskin, D. J., Weinfurt, K. P., Castel, L. D., DePuy, V., Li, Y., Balshem, A. M., Benson, A. B., Burnett, C. B., Corbett, S. E., Marshall, J. L., et al. (2004) · Medical Decision Making · doi:10.1177/0272989x04271041 · Cited by 26
Self-citationWillman, V. L. (2023) · Elsevier eBooks · doi:10.1016/c2021-0-02722-x · Cited by 15
Cited by
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., Wallace, W. H., Wang, E. T., & Loren, A. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1914 · Cited by 1,486
Zafar, S. Y., Peppercorn, J. M., Schrag, D., Taylor, D. H., Goetzinger, A. M., Zhong, X., & Abernethy, A. P. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0279 · Cited by 1,130
Self-citationAntiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Metadata
- Authors
- Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-10
- Volume
- 27
- Issue
- 23
- Pages
- 3868-3874
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170915815
- Cited by
- 638
- References
- 30
- FWCI
- 85.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.